Perrigo ROA 2006-2018 | PRGO
Current and historical return on assets (ROA) values for Perrigo (PRGO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Perrigo ROA for the three months ending September 30, 2018 was 5.96%.
| Perrigo ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-09-30 | $0.12B | $10.94B | 1.07% |
| 2018-06-30 | $0.24B | $11.23B | 2.03% |
| 2018-03-31 | $0.13B | $11.64B | 1.10% |
| 2017-12-31 | $0.12B | $11.63B | 0.97% |
| 2017-09-30 | $-1.31B | $11.84B | -10.19% |
| 2017-06-30 | $-2.95B | $11.79B | -21.23% |
| 2017-03-31 | $-3.41B | $13.98B | -22.00% |
| 2016-12-31 | $-4.01B | $13.87B | -23.76% |
| 2016-09-30 | $-2.83B | $15.89B | -15.48% |
| 2016-06-30 | $-0.98B | $18.29B | -5.08% |
| 2016-03-31 | $-0.46B | $19.50B | -2.37% |
| 2015-12-31 | $0.04B | $19.35B | 0.23% |
| 2015-09-30 | $0.29B | $19.70B | 1.59% |
| 2015-06-30 | $0.12B | $19.72B | 0.74% |
| 2015-03-31 | $0.14B | $16.18B | 0.96% |
| 2014-12-31 | $0.21B | $16.46B | 1.48% |
| 2014-09-30 | $0.06B | $13.78B | 0.42% |
| 2014-06-30 | $0.07B | $13.88B | 0.62% |
| 2014-03-31 | $0.07B | $13.74B | 0.76% |
| 2013-12-31 | $0.14B | $13.71B | 1.89% |
| 2013-09-30 | $0.33B | $5.51B | 6.70% |
| 2013-06-30 | $0.32B | $5.35B | 7.10% |
| 2013-03-31 | $0.32B | $4.50B | 7.65% |
| 2012-12-31 | $0.33B | $4.29B | 7.96% |
| 2012-09-30 | $0.32B | $4.12B | 7.99% |
| 2012-06-30 | $0.29B | $4.02B | 7.37% |
| 2012-03-31 | $0.29B | $4.04B | 7.79% |
| 2011-12-31 | $0.26B | $3.94B | 7.57% |
| 2011-09-30 | $0.25B | $3.51B | 7.86% |
| 2011-06-30 | $0.25B | $3.19B | 8.48% |
| 2011-03-31 | $0.25B | $3.04B | 8.54% |
| 2010-12-31 | $0.23B | $2.94B | 8.00% |
| 2010-09-30 | $0.20B | $2.77B | 7.28% |
| 2010-06-30 | $0.18B | $3.11B | 6.69% |
| 2010-03-31 | $0.18B | $2.49B | 7.08% |
| 2009-12-31 | $0.16B | $2.46B | 6.51% |
| 2009-09-30 | $0.12B | $2.41B | 5.05% |
| 2009-06-30 | $0.11B | $2.54B | 4.43% |
| 2009-03-31 | $0.11B | $2.37B | 4.41% |
| 2008-12-31 | $0.10B | $2.43B | 4.24% |
| 2008-09-30 | $0.11B | $2.51B | 4.80% |
| 2008-06-30 | $0.11B | $2.58B | 4.93% |
| 2008-03-31 | $0.11B | $2.20B | 5.33% |
| 2007-12-31 | $0.09B | $2.04B | 4.36% |
| 2007-09-30 | $0.07B | $1.95B | 3.78% |
| 2007-06-30 | $0.06B | $1.93B | 2.94% |
| 2007-03-31 | $0.06B | $1.89B | 3.01% |
| 2006-12-31 | $0.06B | $1.85B | 3.33% |
| 2006-09-30 | $0.06B | $1.82B | 3.64% |
| 2006-06-30 | $0.06B | $1.75B | 3.47% |
| 2006-03-31 | $0.06B | $1.67B | 3.50% |
| 2005-12-31 | $-0.34B | $1.68B | -20.03% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $8.596B | $4.946B |
| Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $126.543B | 19.40 |
| Abbott Laboratories (ABT) | United States | $126.526B | 25.64 |
| Stryker (SYK) | United States | $64.420B | 24.28 |
| Boston Scientific (BSX) | United States | $51.491B | 26.02 |
| Baxter (BAX) | United States | $35.393B | 22.86 |
| Zimmer Biomet Holdings (ZBH) | United States | $23.875B | 15.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.038B | 0.00 |
| ResMed (RMD) | United States | $14.846B | 28.31 |
| Bio-Rad Laboratories (BIO) | United States | $8.274B | 52.91 |
| Canopy Growth (CGC) | Canada | $8.174B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.270B | 19.88 |
| Aurora Cannabis (ACB) | Canada | $6.172B | 33.68 |
| Haemonetics (HAE) | United States | $5.727B | 50.36 |
| ICU Medical (ICUI) | United States | $4.968B | 27.68 |
| Insulet (PODD) | United States | $4.838B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.052B | 0.00 |
| Hutchison China MediTech (HCM) | China | $4.010B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.990B | 0.00 |
| Neogen (NEOG) | United States | $3.294B | 49.88 |
| NuVasive (NUVA) | United States | $3.166B | 29.46 |
| National Vision Holdings (EYE) | United States | $3.024B | 58.49 |
| Quidel (QDEL) | United States | $2.507B | 32.68 |
| Aphria (APHA) | $2.433B | 0.00 | |
| NxStage Medical (NXTM) | United States | $1.933B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.409B | 19.95 |
| AtriCure (ATRC) | United States | $1.241B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.058B | 1524.50 |
| VAREX IMAGING (VREX) | United States | $0.999B | 20.07 |
| Meridian Bioscience (VIVO) | United States | $0.823B | 26.23 |
| Surmodics (SRDX) | United States | $0.794B | 121.41 |
| OraSure Technologies (OSUR) | United States | $0.772B | 43.48 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.756B | 24.24 |
| MacroGenics (MGNX) | United States | $0.740B | 0.00 |
| Cerus (CERS) | United States | $0.716B | 0.00 |
| PetIQ (PETQ) | United States | $0.705B | 20.03 |
| Lantheus Holdings (LNTH) | United States | $0.625B | 19.34 |
| Omeros (OMER) | United States | $0.619B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.540B | 26.52 |
| Owens & Minor (OMI) | United States | $0.535B | 6.05 |
| Insys Therapeutics (INSY) | United States | $0.527B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.521B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.444B | 0.00 |
| Evolus (EOLS) | United States | $0.403B | 0.00 |
| Quanterix (QTRX) | United States | $0.376B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.332B | 21.45 |
| Cytosorbents (CTSO) | United States | $0.313B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.264B | 0.00 |
| Surface Oncology (SURF) | United States | $0.225B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.214B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.204B | 275.00 |
| Chimerix (CMRX) | United States | $0.172B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.146B | 0.00 |
| Fonar (FONR) | United States | $0.141B | 7.06 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.123B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.106B | 0.00 |
| United-Guardian (UG) | United States | $0.080B | 16.85 |
| Female Health (VERU) | United States | $0.075B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.066B | 21.07 |
| CAS Medical Systems (CASM) | United States | $0.053B | 0.00 |
| Neurotrope (NTRP) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.029B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.018B | 0.00 |
| Senestech (SNES) | United States | $0.017B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
